A rare case of orbital apex syndrome with herpes zoster ophthalmicus in a human immunodeficiency virus-positive patient

Saxena, Rohit; Phuljhele, Swati; Aalok, Lalit; Sinha, Ankur; Menon, Vimla; Sharma, Pradeep; Mohan, Anant
November 2010
Indian Journal of Ophthalmology;Nov2010, Vol. 58 Issue 6, p527
Academic Journal
Case Study
We report a rare instance of favorable outcome in orbital apex syndrome secondary to herpes zoster ophthalmicus (HZO) in a human immunodeficiency virus (HIV)-positive patient. The patient complained of pain and decrease in vision in one eye (20/640) for 2 weeks accompanied with swelling, inability to open eye, and rashes around the periocular area and forehead. The presence of complete ophthalmoplegia, ptosis, relative afferent pupillary defect, and anterior uveitis with decreased corneal sensation prompted a diagnosis of HZO with orbital apex syndrome. The enzyme-linked immunosorbent assay test and a low CD4 count confirmed HIV. Highly active antiretroviral therapy (HAART), systemic acyclovir, and systemic steroids were started. Visual acuity and uveitis improved within 10 days. By the end of the fourth week, ocular motility also recovered and the final visual acuity was 20/25. We highlight the role of HAART, used in conjunction with systemic steroid and acyclovir therapy, in improving the outcome.


Related Articles

  • Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India. N. Kumarasamy; Kartik K. Venkatesh; Bella Devaleenol; S. Poongulali; S. N. Mothi; Suniti Solomon // Journal of Tropical Pediatrics;Jun2009, Vol. 55 Issue 3, p155 

    HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with...

  • Effects of Antiretroviral Agents on Lipid Panels. Song, Jessica C. // AIDS Alert;Dec2007, Vol. 22 Issue 12, p139 

    The article focuses on the impact of highly active antiretroviral therapy (HAART) on lipid panels of HIV-infected patients.

  • South African study shows how few eligible patients start ART.  // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p2 

    The article discusses a study by I. V. Bassett et al published in the January 2010 issue of the journal "AIDS" which indicated the number of eligible patients who start antiretroviral therapy (ART) during the first year of being diagnosed with HIV.

  • Kaposi Sarcoma–Associated Immune Reconstitution Inflammatory Syndrome: In Need of a Specific Case Definition. Letang, Emilio; Naniche, Denise; Bower, Mark; Miro, Jose M. // Clinical Infectious Diseases;Jul2012, Vol. 55 Issue 1, p157 

    A letter to the editor is presented in response to the article "Paradoxicalimmune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection by C.J. Achenbach in a 2011 issue.

  • Leprosy revealed with HIV treatment. Kemper, Carol A. // Infectious Disease Alert;Jun2007, Vol. 26 Issue 9, p107 

    The article reports on the worsening cases of previously unrecognized leprosy among human immunodeficiency virus (HIV) positive persons who are receiving highly active antiretroviral therapy (HAART). It says that approximately 300,000 new cases of leprosy are being diagnosed, mostly in Brazil,...

  • Alteration in Lipid Profile in Treatment-Naive HIV-Infected Patients and Changes Following HAART Initiation in Haryana. Singh, Jagjeet; Verma, Monica; Ghalaut, Pratap Singh; Verma, Renuka; Soni, Abhishek; Ghalaut, Veena Singh // Journal of Endocrinology & Metabolism;2014, Vol. 4 Issue 1/2, p25 

    Background: Abnormalities of lipid metabolism are common in human immunodeficiency virus (HIV)-infected patients and tend to be accentuated in those receiving highly active antiretroviral therapy (HAART). However, data on lipid profile of treatmentnaive HIV-infected patients in India are...

  • DRV/r monotherapy switch could save Spain €22 million.  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p10 

    The article focuses on a study which examined the cost efficiency of switching from HAART to darunavir with ritonavir (DRV/r) monotherapy for patients with HIV infection in Spain.

  • Bisson GP et al (Clin Infect Dis 2013; 56:1165–73).  // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 7, p1067 

    A correction to the article "Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis" that was published in the April 15, 2013 issue is presented.

  • The relationship between smoking, clinical manifestations, and HAART in Nigerian HIV-infected patients. Tanimowo, M. O.; Akinboro, A. O.; Opadijo, O. G.; Akinleye, C. A. // Annals of African Medicine;Dec2014, Vol. 13 Issue 4, p230 

    A letter to the editor is presented related to the relationship between clinical manifestations, smoking, and highly active antiretroviral therapy in Nigerian HIV?infected patients in the October-December 2014 issue.


Other Topics